hTERT promoter methylation in pituitary adenomas

Michaela Köchling(University Hospital Münster), Benjamin Brokinkel(University Hospital Münster), Gina Fürtjes(University of Cologne), Susanne Peetz‐Dienhart(University Hospital Münster), Christian Ewelt(University of Münster), Björn Koos(University Hospital Münster), Werner Paulus(Institute of Neuroimmunology of the Slovak Academy of Sciences), Walter Stummer(University of Münster), Martin Hasselblatt(University Hospital Münster)
Brain Tumor Pathology
September 21, 2015
10.1007/s10014-015-0230-8
Cited by 19

Related Papers

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
|The Lancet Oncology|2006|3.4k
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
|Neurosurgery|2008|1k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Fluorescence-guided resection of glioblastoma multiforme utilizing 5-ALA-induced porphyrins: a prospective study in 52 consecutive patients
|Journal of neurosurgery|2000|880
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
|The Lancet|2019|581